- Home
- LINC vs ARVN Comparison
LINC vs ARVN Comparison
Compare LINC & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LINC | ARVN |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 732.0M | 781.0M |
| IPO Year | 2005 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LINC | ARVN |
|---|---|---|
| Price | $26.13 | $13.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 23 |
| Target Price | ★ $28.25 | $18.14 |
| AVG Volume (30 Days) | 280.9K | ★ 753.9K |
| Earning Date | 02-23-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.12 | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $494,742,000.00 | $312,300,000.00 |
| Revenue This Year | $17.79 | $10.55 |
| Revenue Next Year | $9.52 | N/A |
| P/E Ratio | $56.91 | ★ N/A |
| Revenue Growth | 16.90 | ★ 93.86 |
| 52 Week Low | $14.10 | $5.90 |
| 52 Week High | $28.22 | $20.38 |
Technical Indicators
Market Signals| Indicator | LINC | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 50.54 | 57.38 |
| Support Level | $25.31 | $12.88 |
| Resistance Level | $27.45 | $14.14 |
| Average True Range (ATR) | 1.15 | 0.70 |
| MACD | -0.21 | 0.02 |
| Stochastic Oscillator | 15.59 | 67.89 |
Price Performance
Historical ComparisonAbout LINC Lincoln Educational Services Corporation
Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services, and business and information technology. Its reportable segments include; Campus Operations, and Transitional. The majority of the revenue is generated from the Campus Operations segment which includes all campuses that are continuing in operation and contribute to the Company's core operations and performance.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.